Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Drug Therapy, Combination
Female
Humans
Interferon alpha-2
/ administration & dosage
Male
Melanoma
/ drug therapy
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Skin Neoplasms
/ drug therapy
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
04
11
2020
revised:
13
12
2020
accepted:
16
03
2021
pubmed:
24
3
2021
medline:
2
4
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therapy in patients with resectable advanced melanoma. Patients with resectable stage III/IV melanoma were treated with concurrent pembrolizumab 200 mg i.v. every 3 weeks and HDI 20 MU/m A total of 31 patients were enrolled, and 30 were evaluable. At data cutoff (October 2, 2019), median follow-up for OS was 37.87 months (range, 33.2-43.47). Median OS and RFS were not reached. Radiographic ORR was 73.3% [95% confidence interval (CI): 55.5-85.8], with a 43% (95% CI: 27.3-60.1) pCR rate. None of the patients with a pCR have had a recurrence. HDI and pembrolizumab were discontinued in 73% and 43% of patients, respectively. Correlative analyses suggested that intratumoral PD-1/PD-L1 interaction and HLA-DR expression are associated with pCR ( Neoadjuvant concurrent HDI and pembrolizumab demonstrated promising clinical activity despite high rates of treatment discontinuation. pCR is a prognostic indicator.
Identifiants
pubmed: 33753453
pii: 1078-0432.CCR-20-4301
doi: 10.1158/1078-0432.CCR-20-4301
pmc: PMC8338751
mid: NIHMS1688138
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Interferon alpha-2
0
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4195-4204Subventions
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA121973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228181
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2021 American Association for Cancer Research.
Références
J Clin Oncol. 2018 Oct 25;:JCO1800632
pubmed: 30359157
J Surg Oncol. 2018 May;117(6):1164-1169
pubmed: 29228467
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Immunol. 2005 Apr 15;174(8):4465-9
pubmed: 15814665
PLoS One. 2014 Feb 03;9(2):e87705
pubmed: 24498358
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Lancet Oncol. 2019 Jul;20(7):961-971
pubmed: 31171444
J Immunol. 2014 Oct 15;193(8):4254-60
pubmed: 25217157
Curr Treat Options Oncol. 2020 Feb 5;21(2):10
pubmed: 32025932
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751
pubmed: 31040150
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
Lancet Oncol. 2018 Feb;19(2):181-193
pubmed: 29361468
Melanoma Manag. 2019 Oct 18;6(3):MMT27
pubmed: 31807278
Clin Cancer Res. 2018 Nov 1;24(21):5250-5260
pubmed: 30021908
Clin Cancer Res. 2019 Jan 15;25(2):524-532
pubmed: 30420448
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
J Clin Oncol. 2006 Jul 1;24(19):3164-71
pubmed: 16809739
Ther Adv Med Oncol. 2019 Jul 31;11:1758835919866959
pubmed: 31391869
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
J Surg Oncol. 2019 Jan;119(2):216-221
pubmed: 30589079
J Immunol. 2012 Oct 15;189(8):3789-93
pubmed: 23042723
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Lancet Oncol. 2019 Jul;20(7):e378-e389
pubmed: 31267972
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Biochimie. 2007 Jun-Jul;89(6-7):884-93
pubmed: 17532550
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
J Clin Oncol. 2020 Feb 20;38(6):567-575
pubmed: 31880964
Cancer. 2019 Sep 1;125(17):3013-3024
pubmed: 31067358
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Nat Med. 2021 Feb;27(2):301-309
pubmed: 33558722
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Expert Rev Anticancer Ther. 2020 May;20(5):403-413
pubmed: 32326767
Transl Oncol. 2021 Mar;14(3):101014
pubmed: 33450703
Br J Dermatol. 2020 Sep;183(3):559-563
pubmed: 31773720
J Immunother Cancer. 2018 Oct 23;6(1):112
pubmed: 30352626